Economy
Isomorphic Labs, Alphabet's drug subsidiary, is reportedly discussing raising $40 billion to $50 billion
Five months after a $2.1 billion Series B, Demis Hassabis' company is reportedly aiming for more than double its valuation, without having yet tested a single AI-designed drug in humans.